Here is the link:
http://jcp.bmj.com/cgi/content/full/58/6/611 The title is "Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer."
The authors evaluated 1362 women from 2000-2003 in a single hospital in Belgium. The statistics they generated are very interesting. They concluded : "In women with ER+ tumours, the expression of PR affects the likelihood of HER-2/neu overexpression, and it may be that women with ER+ PR– tumours should be targeted with more aggressive treatment than those with ER+ PR+ tumours."
Hope this helps,
Hopeful
Threaded Mode